Endocyte Inc., of West Lafayette, Ind., presented final overall survival (OS) analysis from the phase IIb TARGET trial of small-molecule-drug conjugate vintafolide in combination with docetaxel in patients with folate receptor-positive recurrent non-small-cell lung cancer (NSCLC) at the World Conference on Lung Cancer in Denver.